2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, APL, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5188 A multicenter, retrospective study of HMA + venetoclax + FLT3 inhibition vs HMA + venetoclax as frontline treatment for newly-diagnosed FLT3-mutant AML

Andrew McKeithan Brown, MD, Katherine Gamel Atkinson, DO2, Calvin Widholm3, Georgio Medawar, MD4, Hannah Pearl5, Breanna Yang6, Stephanie Begley, MS7, Brooke Charria, MD8, Kapil Meleveedu, MD9, David Swoboda, MD10, Brittany Knick Ragon, MD11, Douglas Tremblay, MD12, Joshua F. Zeidner, MD13, Alexander Coltoff, MD14
1 Medical University of South Carolina, Charleston, South Carolina, United States
2 Medical University of South Carolina, Charleston, South Carolina, United States
3 Medical University of South Carolina, Charleston, South Carolina, United States
4 Medical University of South Carolina, Charleston, South Carolina, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
8 Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut, Farmington, Connecticut, United States
9 Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut, Farmington, Connecticut, United States
10 Tampa General Hospital, Tampa, Florida, United States
11 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
12 Icahn School of Medicine at Mount Sinai, New York, New York, United States
13 University of North Carolina, Chapel Hill, North Carolina, United States
14 Medical University of South Carolina, Charleston, South Carolina, United States

Background: The standard of care for patients with newly diagnosed acute myeloid leukemia (ND AML) ineligible for intensive chemotherapy is a hypomethylating agent (HMA) + venetoclax (VEN). Although response rates to HMA + VEN are similar regardless of FLT3 mutational status, FLT3-ITD mutations are associated with shorter remissions and inferior survival (Dohner et al, Blood 2024). Single-arm studies (Short et al, JCO 2024) have reported efficacy of triplet-therapies of HMA + VEN + FLT3 inhibitor (FLT3i), but are limited by lack of a comparator group. Given the increasing use of non-intensive induction in ND AML, there is a need to better evaluate the benefit of this novel therapeutic approach.

Objective: To compare the safety and efficacy of the triplet combination of HMA + VEN + FLT3i to the combination of HMA + VEN for ND FLT3-mutant AML.

Methods: Retrospective chart review at 6 centers of adult patients with ND FLT3-mutant AML treated with HMA+VEN+FLT3i (Triplet) or HMA+VEN (Doublet) between 11/2018 and 3/2026. Primary outcomes included the rate of complete remission (CR), CR with incomplete hematologic recovery (CRi), event-free survival (EFS), leukemia-free survival (LFS) and overall survival (OS). Additional outcomes included rate of stem cell transplantation (HSCT) and treatment-related toxicity. Median follow-up was estimated using the reverse Kaplan-Meier method. Survival analyses were assessed using Kaplan-Meier methods. Differences in survival outcomes between treatments were compared using the log-rank test.

Results: A total of 109 patients were included (Triplet: n=38 vs. Doublet: n=71). Median follow-up of the patient population was 30.9 months (95% CI, 28.4 – 47.9 months).  Median age at diagnosis was 69 years (range, 19 – 82 years) in the Triplet group and 74 years (range, 25 – 90 years) in the Doublet group (p = 0.003). FLT3-ITD mutations were present in 84.2% of patients in the Triplet group vs 63.4% in the Doublet group, and FLT3-TKD occurred in 5.3% of patients in the Triplet group vs 29.6% in the Doublet group (p = 0.005). Subtypes of AML (i.e., de novo, secondary, therapy-related) and incidence of normal/abnormal karyotypes were balanced between the two groups.

All patients received either decitabine or azacitidine (no patients received oral decitabine-cedazuridine in C1). Decitabine was used in the majority of patients (68.4%) in the Triplet group and in 23.9% of patients in the Doublet group (p < 0.001). FLT3i use in C1 consisted of gilteritinib (44.7% of patients), midostaurin (42.1%), quizartinib (7.9%), and sorafenib (5.3%).

CR/CRi rates after C1 (63.2% vs 58.5%, p = 0.6) and at the time of best response (77.7% vs 76.8%, p > 0.9) were similar between the Triplet and Doublet groups, respectively. The median number of cycles to best response were similar in the Triplet and Doublet groups, respectively (2 vs 1, p = 0.3). For patients with C1 and C2 dates, median days between C1 and C2 was 38 days in the Triplet group, and 39 days in the Doublet group (p = 0.7). Median EFS in the Triplet group was 6.45 months [95% CI 0.02-NR] vs 7.42 months [95% CI 4.9-11.47] in the Doublet group (p = 0.072). Median OS was not reached [95% CI 24.87 - NR] in the Triplet group vs 13.52 months [95% CI 10.13 - 21] in the Doublet group (p = 0.012). Median LFS was not reached [95% CI 11.23-NR] in the Triplet group vs 9.23 months [95% CI 7.68-18.93] in the Doublet group (p = 0.009).

Blood stream or biopsy proven infections during C1 occurred in 9 patients (24%) in the Triplet group vs 9 patients (15%) in the Doublet group (p = 0.3). Thirteen (34%) patients in the Triplet group and 8 (11%) in the Doublet group were successfully bridged to HSCT. In the HSCT cohort, median OS was not reached [95% CI NR-NR] in the Triplet group, median OS was 29 months [95% CI 15.74-NR] in the Doublet group.

Conclusions: The triplet regimen of HMA + VEN + FLT3i was associated with improved LFS and OS compared to standard HMA + VEN despite no difference in EFS or CR/CRi rates. Possible explanations for this finding include a higher rate of HSCT and/or decreased incidence of relapse with incorporation of FLT3i. The ongoing randomized, prospective phase II MM1OA-EA02 study of a FLT3i-containing triplet regimen vs HMA+VEN will provide further insight regarding the optimal treatment of ND FLT3-mutant AML. Data synthesized from such clinical trials and real-world studies will be crucial to inform the best care for this patient population.

Andrew McKeithan Brown, MD: No relevant conflicts of interest to declare.